Is Biophytis S.A. (ALBPS.PA) a Buy, Sell, or Hold?
PAR : ALBPS.PA
Biophytis S.A.
$0.0153 EUR
$0 (0.0%)
- Volume
- 1.91M
- Average Volume
- 3.74M
- Market Capitalization
- $355.43K
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.22
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.25
Company Overview
PAR
Stanislas Veillet
Biotechnology
Healthcare
ALBPS.PA
22
FR
EUR
Liquidity Metrics
-1.02
0.25
0.25
0.00
0.00
Sales & Valuation
-$
0.00
-0.01
-0.04
-1.67
Profitability
-$2
-$10.38M
0.00%
0.00%
153.48%
-150.38%
P/E Metrics
-0.01
0.00
0.00
Analyst Price Target & Rating
0/5
1 Analysts
%
Financial Health Scores
-17.06
2/9
-$7.14M
$6.62M
$14.44M
-$19.34M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Edouard Bieth | Chief Strategy Officer |
| Stanislas Veillet | Chairman of the Board & Chief Executive Officer |
| Teylan | Financial Controller |
| Pierre J. Dilda | Chief Scientific Officer |
| Waly Dioh | Chief Operating Officer |
| Rene Lafont | Scientific Advisor & Member of Scientific Advisory Board |
| Christophe Courtillat | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Biophytis S.A. (PAR:ALBPS.PA) Stock
Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermor ... e, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.
Frequently Asked Questions
-
What is the current Biophytis S.A. (ALBPS.PA) stock price?
-
Biophytis S.A.(PAR:ALBPS.PA) stock price is $0.0153 in the last trading session. During the trading session, ALBPS.PA stock reached the peak price of $0.218 while $0.0153 was the lowest point it dropped to. The percentage change in ALBPS.PA stock occurred in the recent session was 0.0% while the dollar amount for the price change in ALBPS.PA stock was $0.
-
ALBPS.PA's industry and sector of operation?
-
The PAR listed ALBPS.PA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALBPS.PA?
-
Edouard Bieth | Chief Strategy Officer
Stanislas Veillet | Chairman of the Board & Chief Executive Officer
Teylan | Financial Controller
Pierre J. Dilda | Chief Scientific Officer
Waly Dioh | Chief Operating Officer -
How many employees does ALBPS.PA have?
-
Number of ALBPS.PA employees currently stands at 22. ALBPS.PA operates from Sorbonne University, Paris, IF 75005, FR.
-
Link for ALBPS.PA official website?
-
Official Website of ALBPS.PA is: https://www.biophytis.com
-
How do I contact ALBPS.PA?
-
ALBPS.PA could be contacted at phone #33 1 44 27 23 00 and can also be accessed through its website. ALBPS.PA operates from Sorbonne University, Paris, IF 75005, FR.
-
How many shares of ALBPS.PA are traded daily?
-
The average number of ALBPS.PA shares traded daily for last 3 months was 3.74M.
-
What is the market cap of ALBPS.PA currently?
-
The market value of ALBPS.PA currently stands at $355.43K with its latest stock price at $0.0153